OGN vs VRTX · P/E 3.4, rev $6.40B vs P/E 30, rev $12.00B
Organon & Co (OGN) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
OGN currently screens at market cap $2.52B and trailing P/E 3.4. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the OGN and VRTX stock pages for the full models.
Not investment advice.